Trial Profile
A Phase 2 Trial of Daily Alternating Thalidomide and Lenalidomide Plus Rituximab (ThRiL) for Patients With Previously Treated Waldenstrom Macroglobulinemia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 11 Apr 2017
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Thalidomide (Primary) ; Rituximab
- Indications Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 01 May 2014 Trial status changed to discontinued as reported by ClinicalTrials.gov.
- 05 Feb 2013 New trial record